Effectiveness of convalescent plasma therapy in a patient with severe covid-19-associated acute kidney injury

The outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly evolved into a global pandemic. Recent findings indicate an increased risk for kidney involvement, including progressive acute kidney injury (AKI) during COVID-19 infection, specifi-cally in critically ill patients, and associated with high mortality rates. As no specific treatment options exist for AKI secondary to COVID-19, intensive care is largely support-ive with a frequent need for renal replace-ment therapy (RRT). Convalescent plasma (CP) has been approved as an emergency investigational drug with clinical benefits in observational studies. We described a first case of a patient with severe COVID-19 and AKI who had remarkable improvement in his respiratory status and in kidney function following CP therapy. Our findings demon-strate important therapeutic implications of effective multimodality therapy including CP when treating patients with COVID-19 and AKI.